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Editorial
Percutaneous Implantation of Valvular Aortic 
Bioprosthesis: Reconciling the Clinical and Economic 
Values of an Established Treatment
Dimytri Alexandre Siqueira1, Alexandre A. C. Abizaid2, Susheel Kodali3, Martin B. Leon4
O ver the past decades, major advances have been made in the percutaneous treatment of structural heart diseases. Among the procedures 
used for this purpose, the transcatheter aortic valve 
implantation (TAVI; also known as transcatheter aortic 
valve replacement [TAVR]) has a prominent role, due 
to its proved effectiveness in promoting symptomatic 
benefits and reducing the mortality of elderly patients 
with aortic stenosis and unable to surgery,1 who are 
frequently attended to in clinical practice and who 
formerly had no alternative therapy for a disease with 
mortality rates of up to 75% after three years, or 2% 
per month.2 Driven by the continuous accumulation 
of evidence (from large registries3,4 and randomized 
trials),1,5 by the rapid development in tools, and by 
the vast technical experience, TAVR was adopted 
worldwide, and its indication is already established in 
Brazilian and international guidelines.6,7 Currently, it 
is recommended that TAVR should be the treatment of 
choice for patients with severe aortic stenosis deemed 
inoperable (class I, level of evidence B), being an al-
ternative strategy for surgical aortic valve replacement 
(SAVR) in those patients at high surgical risk (class IIa, 
level of evidence B).
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Since the first implant, in 2002,8 it is estimated 
that over 90,000 patients have undergone TAVR world-
wide. Currently, two types of prostheses implanted via 
femoral access are available in Brazil (Sapien XT, 
Edwards Life sciences; and CoreValve, Medtronic Inc.), 
and it is estimated that approximately 700 patients 
have been treated with this technique in that country. 
Obviously, this number is well below the potential 
universe of patients referred for TAVR, if considering 
that: (1) currently Brazil has over 9 million people 
above the age of 70 years;9 (2) a recently published 
trial demonstrated that the prevalence of severe aortic 
stenosis is 3.4% in this age group, and approximately 
40% of these patients are not candidates for surgery; 
from this universe of individuals without surgical 
possibility, approximately 40% would be indicated 
for TAVR.10 In this scenario, there would be over 
45,000 patients who potentially would benefit from 
TAVR in Brazil. The lack of reimbursement for TAVR 
by public and supplemental health systems is one of 
the main reasons for the lack of a wider adoption of 
this procedure in that country.
Due to the increasing health expenditures observed 
globally, it is essential to carefully assess the effective-
ness and costs of new technologies, aiming to promote 
a proper allocation of limited and finite resources. 
In the context of interventional cardiology, few of 
those effective diagnostic and therapeutic innovations 
introduced in daily practice are initially of low cost. 
The question could not be different with TAVR; it is 
therefore relevant to discuss the cost-effectiveness of 
this new procedure, since, as stated, there is no other 
treatment option capable of changing the inexorable 
course of the disease for many patients.
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TAVR is a treatment of great clinical value
Several trials have demonstrated the effectiveness 
of TAVR, with high success rates; the mortality rate 
has been significantly lower than the surgical mortality 
predicted by risk scores (EuroSCORE and STSPROM).1,3-5 
The procedure is effective in relieving stenosis, with 
sharp reduction of the transvalvar gradient and with 
achievement of valve areas comparable with, if not 
greater than, those observed after SAVR. The longer-term 
follow-up suggests that this acute result persists for at 
least five years.11 One of the most rewarding aspects of 
TAVR is the dramatic improvement in symptoms and 
quality of life after treatment, which has been demon-
strated in all trials. Complications associated with the 
procedure, such as stroke, vascular events, and bleeding 
are worrisome, but the frequency of these events has 
decreased with the use of new devices and increased 
experience.12
In the first randomized clinical trial on this treat-
ment, the Placement of AoRTic TraNscathetER Valves 
(PARTNER) cohort B1, 358 elderly patients (mean age: 
83 years) with severe symptomatic aortic stenosis (93% 
of patients in New York Heart Association [NYHA] func-
tional class III or IV) and with prohibitive surgical risk, 
were randomized to TAVR with the Edwards SAPIEN 
prosthesis or to optimal medical treatment, which often 
included aortic balloon valvuloplasty. In fact, the patients 
included are representative of real-world practice, with 
multiple comorbidities and adverse prognosis. After 12 
months, a significant reduction in mortality with TAVR 
was observed, compared with medical therapy (30.7% 
vs. 50.7%, P < 0.001); this benefit was consistent across 
all subgroups analyzed, with a number needed to treat 
(NNT) of 5 for one-year mortality. The life expectancy 
of patients undergoing the procedure increased from 
1.2 to 3.1 years; lowest rate of new hospitalizations and 
significant improvement in left ventricular dysfunction 
constituted other benefits arising from the implantation 
of the prosthesis. By combining the outcomes of qual-
ity of life (QOL) with survival data – defining staying 
alive as a favorable evolution and with an increase of 
10 points in a specific questionnaire for patients with 
heart failure (Kansas City Cardiomyopathy Question-
naire) – 48% of patients treated with TAVR and 14% 
of clinically treated patients experienced a satisfactory 
outcome.13 Notably, approximately 25% of patients 
undergoing TAVR achieved excellent evolution, and 
were classified as NYHA functional class I after 12 
months. In a further analysis, it was demonstrated that 
the benefits observed in terms of survival, hospitaliza-
tions, and symptoms were maintained after two years 
of evolution.14
Other registries, such as SOURCE XT (consisting 
of 1,694 patients treated with Sapien XT prosthesis 
by femoral route) and ADVANCE (1,015 patients who 
underwent implantation of the CoreValve prosthesis), 
indicators of real world outcomes, confirmed the ex-
cellent results of randomized trials, with success rates 
of up to 95%, and with survival rates after 30 days 
between 87% and 95.7%.
Would TAVR be a treatment of appropriate 
economic value?
Economic analyses in health care are based on 
comparisons between new therapy with current treat-
ments, assessing not only the costs, but also the dif-
ferences in clinical efficacy. Although there are other 
possibilities, such assessments are needed when the 
new treatment in question is more effective, but has 
higher cost. The main types of economic evaluation 
are: cost-effectiveness and cost-utility.15
Cost-effectiveness is the most common form of 
economic analysis in health, and reveals the balance 
between the benefits and costs of a new treatment or 
a new approach. In general, cost-effectiveness analysis 
is measured in increased cost per unit of effectiveness 
(e.g., years of life saved) or by the incremental cost-
effectiveness ratio (ICER). Conversely, the analysis of 
cost-utility assesses not only the ultimate goal of treat-
ment (survival), as well as its influence in the quality 
of life of the patient (e.g., symptoms), and is expressed 
in quality-adjusted life years (QALY).16
Several studies have been published on the cost-
effectiveness of TAVR versus medical therapy in patients 
deemed inoperable. The biggest study was based on 
individual data from each of the patients included in 
the PARTNER B cohort trial. Estimating the total cost 
of the procedure at US$ 79,000 (including hospitaliza-
tion, physicians’ fees, and the cost of the prosthesis of 
US$ 35,000), TAVR resulted in an ICER of US$ 50,212, 
with QALY of US$ 62,000.13
Recently introduced, the Brecker economic trial 
used data from 12 months’ survival of patients treated 
with CoreValve system and included in the ADVANCE 
registry, comparing them to the medical treatment group 
of the PARTNER B trial.17 Considering the health values 
practiced in the United Kingdom, the cost per QALY 
with the CoreValve prosthesis was £11,265. Other 
analyses also based on the overall results of PARTNER 
cohort B trial, used Markov statistical models. A Can- 
adian analysis by Doble et al. demonstrated an ICER 
of CAD 36,458 per additional year of life and CAD 
51,324 per QALY.18 Analyzing the context of the United 
Kingdom, Watt et al. estimated £16,100 per QALY, in a 
time-horizon of ten years.19 Despite some differences in 
the methodology and estimated economic costs of the 
procedure, the results of these trials suggest that TAVR 
is an economically acceptable treatment for inoperable 
patients, determining an incremental cost that is simi-
lar to other medical treatments already implemented, 
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such as implantable cardioverter-defibrillators, lung 
transplantation, and haemodialysis.
However, it could be argued that such results in 
international scenarios are not applicable to the Brazil-
ian situation, especially because of differences regard-
ing expenditures, in the health sector, among different 
countries. In the present issue of Revista Brasileira de 
Cardiologia Invasiva, Queiroga et al.20 evaluate, in 
a detailed study from the perspective of the private 
healthcare system, the ICER of TAVR in Brazil. Using 
estimates of the direct medical costs of the procedure 
(regarding hospital admission, the procedure itself, and 
administered medications) and the predictive statistical 
model based on the results of the PARTNER B trial, the 
authors performed an economic analysis of TAVR on 
the national scene. Taking as reference R$ 65,000.00 
as the prosthesis value, the authors reported that the 
total cost of treatment with TAVR after five years was 
R$ 123,019.76; of this total, R$ 35,815.12 were spent 
with the conservative strategy. Estimating an improved 
survival with TAVR compared with the clinical treat-
ment, the ICER was R$ 90,161.29 in five years and R$ 
55,130.84 in a time-horizon of ten years.
Based on these values of cost-effectiveness, are 
there conditions to finance them? From the public health 
standpoint, some countries (United States, Canada and 
England, for instance) set acceptable thresholds for 
cost-effectiveness ratios, considering new treatments or 
devices. For example, trials conducted in the United 
States define as a favorable threshold US$ 50,000 per 
QALY; in Canada, such value is between 20,000 and 
40,000 Canadian dollars. In England, the threshold 
is estimated at £40,000. In Brazil, the World Health 
Organization suggests as a threshold a value of up to 
three times the gross domestic product (GDP) per capita, 
or approximately R$ 78,239.00 in 2012. However and 
as previously emphasized in this article, the Brazilian 
Ministry of Health established an even greater limit for 
ICER, of US$ 50,000. In the trial in question, the ICER 
for TAVR is situated below that threshold. Unfortunately, 
the extrapolation of these relationships to the area of 
private healthcare is controversial.
Some limitations of this article should be highlight-
ed. First, the clinical benefits obtained by TAVR were 
considered constant during the time-horizon of five to 
ten years, although published data from clinical trials 
have follow-up periods of only two years. In these and 
other trials, the rates of long-term mortality are consist- 
ent with the age group and associated comorbidities 
(pulmonary, renal, and neurological diseases, as well 
as neoplasias), and approximately half of the deaths 
during the follow-up had, in many studies, noncardiac 
etiology. Therefore, considering an elderly population 
with major illnesses associated, it is concluded that the 
clinical benefits of the intervention decrease with time. 
In the PARTNER B trial, the prosthesis used was of an 
earlier generation (Edwards SAPIEN) in comparison to 
that used in Brazil, and was associated with a higher 
incidence of bleeding and vascular complications – 
which can increase mortality and raise the costs of 
hospitalization. Another aspect to be discussed is the 
estimation of aortic valvuloplasty utilization, performed 
on the group of patients who received clinical treat-
ment; in recent years, an increase in the indication for 
this procedure has been observed, aiming to promote 
symptomatic benefit to individuals for whom the im-
plant of prosthesis is not possible for various reasons, 
including lack of reimbursement. The inclusion of the 
costs of aortic valvuloplasty in the group of patients 
kept under strict medical treatment could result in even 
lower values of ICER in the economic model adopted. 
Finally, it should be noted that the conclusions of the 
article of Queiroga et al.20 are based on the results of 
inoperable patients undergoing TAVR, and should not 
be extrapolated to patients with high surgical risk (as-
sessed in the PARTNER A trial, with specific analysis 
of cost-effectiveness).21
Ultimately, the challenge remains: how assure to 
the patients the high clinical value effectiveness of 
TAVR reconciling them to their high cost economic in 
Brazil? In this sense, it is important to seek strategies 
to improve the ICER of TAVR that involve not only the 
reduction of the cost of the prosthesis. Other recom-
mended measures include compliance with the technical 
aspects of the procedure; prevention of complications; 
earlier mobilization of patients, reducing the length of 
hospital stay; and avoidance of unnecessary additional 
tests to monitor these individuals. Fundamentally, patients 
to be submitted to TAVR must be properly selected: 
those who can not only overcome its risks, but really 
enjoy the long term benefits of this new, efficient, and 
already established treatment.
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